Pharmacologic treatment with GABAB receptor agonist of methamphetamine-induced cognitive impairment in mice

Hiroyuki Mizoguchi, Kiyofumi Yamada

研究成果: ジャーナルへの寄稿学術論文査読

22 被引用数 (Scopus)

抄録

Methamphetamine (METH) is a highly addictive drug, and addiction to METH has increased to epidemic proportions worldwide. Chronic use of METH causes psychiatric symptoms, such as hallucinations and delusions, and long-term cognitive deficits, which are indistinguishable from paranoid schizophrenia. The GABA receptor system is known to play a significant role in modulating the dopaminergic neuronal system, which is related to behavioral changes induced by drug abuse. However, few studies have investigated the effects of GABA receptor agonists on cognitive deficits induced by METH. In the present review, we show that baclofen, a GABA receptor agonist, is effective in treating METH-induced impairment of object recognition memory and prepulse inhibition (PPI) of the startle reflex, a measure of sensorimotor gating in mice. Acute and repeated treatment with METH induced a significant impairment of PPI. Furthermore, repeated but not acute treatment of METH resulted in a long-lasting deficit of object recognition memory. Baclofen, a GABAB receptor agonist, dose-dependently ameliorated the METH-induced PPI deficits and object recognition memory impairment in mice. On the other hand, THIP, a GABAA receptor agonist, had no effect on METH-induced cognitive deficits. These results suggest that GABAB receptors may constitute a putative new target in treating cognitive deficits in chronic METH users.

本文言語英語
ページ(範囲)109-112
ページ数4
ジャーナルCurrent Neuropharmacology
9
1
DOI
出版ステータス出版済み - 2011
外部発表はい

All Science Journal Classification (ASJC) codes

  • 薬理学
  • 神経学
  • 臨床神経学
  • 精神医学および精神衛生
  • 薬理学(医学)

フィンガープリント

「Pharmacologic treatment with GABAB receptor agonist of methamphetamine-induced cognitive impairment in mice」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル